[Effects of the synthetic proteinase inhibitor, FOY, on hypercoagulability after surgery for esophageal carcinoma].
Hypercoagulability develops after surgery for esophageal carcinoma, and it related closely to postoperative complications. This study evaluated the effects of the synthetic proteinase inhibitor, Cabexate Mesilate (FOY), on this hypercoagulability. The subjects used were 25 patients with a mean age of 63 who had undergone surgery for esophageal carcinoma. Of these, eight patients (test group) received FOY (2,000 mg/day) for three to 23 days after surgery, but 17 (control group) did not. In the test group, FOY controlled aggregation and release of the platelets and minimized their exhaustion. FOY almost completely checked the abnormal increase in thrombin activity which might trigger the hypercoagulability. Also, FOY suppressed the fibrinolytic activity slightly. These results indicate that FOY is effective in controlling hypercoagulability after surgery for esophageal carcinoma and in suppressing activity of the proteinases that cause both blood coagulation and fibrinolysis.
Usuba
A
A
First Department of Surgery, Fukushima Medical College, Japan.
Motoki
R
R
Koizumi
Y
Y
Oishi
A
A
Endo
Y
Y
Konno
O
O
Inoue
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects*; D004938:Esophageal Neoplasms / Q000097:blood* / Q000601:surgery; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D016670:Gabexate; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*
D000925:Anticoagulants; D006146:Guanidines; D015842:Serine Proteinase Inhibitors; D016670:Gabexate